SecBot SecBot
SECBOTREPLAY Home › Report › PVLA

PVLA · Palvella Therapeutics launched the 'BEYOND mLM' disease awareness…

Palvella Therapeutics Inc. · PRESS-RELEASE filed Mar 10, 2026 at 07:30 ET

At the news

NEUTRALIMPACT 3/10

PRESS-RELEASE filed Mar 10, 2026 at 07:30 ET

Palvella Therapeutics launched the 'BEYOND mLM' disease awareness campaign and website (BEYONDmLM.com) to educate patients, caregivers, and healthcare providers about microcystic lymphatic malformations (microcystic LMs), a rare and debilitating condition with no FDA-approved therapies. The campaign was developed in collaboration with leading nonprofit organizations and clinical experts in the vascular anomalies community.

  • Palvella launched BEYONDmLM.com, an educational campaign and website focused on microcystic lymphatic malformations (microcystic LMs).
  • The campaign was developed in partnership with five key nonprofit organizations: CaNVAS, LGDA, LE&RN, PeDRA, and VAccess.org.
  • Microcystic LMs affect over 30,000 diagnosed patients in the U.S. and are characterized by malformed lymphatic vessels causing chronic leakage, bleeding, and recurrent infections.
  • There are currently no FDA-approved treatments for microcystic LMs.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access